At a glance
ClinicalIndex Comparison RecordN/ACompleted· 596 enrolled
Drug / intervention
Avelumabdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
AVENANCE - A Non-interventional Study to Provide Real-world Data on the Use of Avelumab as a Maintenance Treatment for Patients With Advanced or Metastatic Urothelial Carcinoma
In Brief
An observational study evaluating Avelumab for Urothelial Carcinoma. Completed, enrolled 596 participants across 81 sites.
Detailed Summary
A multicenter ambispective (retrospective and prospective) non-interventional study of patients with locally advanced or metastatic urothelial carcinoma (adv/mUC) treated with avelumab in France, not impacting the treatment decision made by the treating physician and the medical management of treated patients.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsUrothelial Carcinoma
CountriesFrance
CollaboratorsMerck KGaA, Darmstadt, Germany
Timeline
N/ACompletedFinished
20222023202420252026
First PostedMar 2021
Enrollment StartJul 2021
Primary CompletionApr 2024
TodayJul 2026
First PostedMar 30, 2021
Enrollment StartJul 13, 2021
Primary CompletionApr 25, 2024
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 5.3 years ago
Interventions
Avelumabdrug
As provided in real world practice